Sidechain structure-activity relationships of cyclobutane-based small molecule αvβ3 antagonists

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Oncology

Background:

• Integrins are crucial cell surface proteins mediating tissue development, cancer progression, and metastasis.
• Integrin antagonists represent promising therapeutic targets for both oncological and non-oncological conditions.

Purpose of the Study:

• To develop a novel integrin antagonist chemotype utilizing a functionalized cyclobutane scaffold.
• To synthesize and evaluate cyclobutane derivatives as arginine-glycine-aspartic acid (RGD) mimetics for targeting integrins, specifically αvβ3.

Main Methods:

• Synthesis of cyclobutanecarboxylic acids and cyclobutylamines featuring tetrahydronaphthyridine/aminopyridine and masked carboxylic acid sidechains.
• Assessment of compounds using cell-based adhesion and invasion assays to identify effective αvβ3 antagonists and aspartic acid mimetics.
• Evaluation of a lead compound for in vitro activity (IC50 < 1 μM), metabolic stability (t1/2 > 80 minutes), and in vivo tolerability.

Main Results:

• Identification of effective αvβ3 antagonists and novel aspartic acid mimetics.
• A lead compound demonstrated potent in vitro activity, favorable stability, and was well-tolerated in vivo.
• Successful development of a robust synthetic route for functionalized cyclobutanes.

Conclusions:

• The developed synthetic strategy using functionalized cyclobutanes is promising for creating αvβ3 antagonists.
• The identified lead compound warrants further preclinical development for potential clinical application.
• Functionalized cyclobutanes serve as metabolically stable scaffolds, expanding their utility in drug discovery.